Temelimab Explained

Drug Name:Temelimab
Type:mab
Mab Type:IgG4
Legal Status:Experimental

Temelimab (also known as GNbAC1[1] ) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2] [3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.[4]

References

  1. Irfan SA, Murtaza M, Ahmed A, Altaf H, Ali AA, Shabbir N, Baig MM . Promising role of temelimab in multiple sclerosis treatment . Multiple Sclerosis and Related Disorders . 61 . 103743 . May 2022 . 35344907 . 10.1016/j.msard.2022.103743 . 247489555 .
  2. Mouliou DS, Dardiotis E . Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? . Multiple Sclerosis and Related Disorders . 64 . 103938 . August 2022 . 35717898 . 9169463 . 10.1016/j.msard.2022.103938 .
  3. Kornmann G, Curtin F . Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review . Drug Safety . 43 . 12 . 1287–1296 . December 2020 . 32794123 . 10.1007/s40264-020-00988-3 . 221126453 .
  4. Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, Fine J, Fontelo P, Kim AY, Shaw G, Stratford J, Ceger P, Costantine MM, Fisher L, O'Brien L, Maughan C, Quigley JG, Gabbay V, Mohandas S, Williams D, McComsey GA . 6 . Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative . Frontiers in Immunology . 14 . 1129459 . 2023-03-09 . 36969241 . 10034329 . 10.3389/fimmu.2023.1129459 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Temelimab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.